The main aim of this study was to investigate the association of polymorphisms in long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) with the risk of esophageal squamous cell carcinoma (ESCC) in a Chinese population. Methods: A total of 245 ESCC patients and 490 gender-and age-matched cancer-free controls were genotyped for four tag single nucleotide polymorphisms (SNPs) of MALAT1 (rs3200401 C . T, rs1122709 C . G, rs664589 C . G, and rs619586 A . G). Statistical analyses including chi-squared test and logistic regression were performed to identify the association between the tag SNPs and risk of ESCC, and false discovery rate (FDR) ,25% was applied to adjust for multiple comparisons. Results: We found that rs3200401 C . (FDR value ,0.25) except for the comparison between rs619586 GG and AA genotype in ever drinking subgroup. Conclusion: Taken together, our findings proposed that polymorphism rs3200401 C . T in MALAT1 gene is associated with increased risk of ESCC. Since the association between rs619586 A . G polymorphism and ESCC risk was not significant after FDR adjustment, there was a minor possibility that rs619586 A . G might be a protective factor for ESCC.
Introduction
Esophageal cancer (EC) is the sixth leading cause of cancer-related death worldwide. 
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Long non-coding RNAs (lncRNAs) are a type of ncRNAs that are more than 200 nucleotides (nts) in length and are unable to encode proteins. 3 They have been found to play important roles in the progress of several common diseases (eg, myocardial infarction and hyperglycemia). [4] [5] [6] In malignant tumors, increasing number of lncRNAs were found to have important functions in the process of genesis, progress, and treatment response of tumor cells. [7] [8] [9] Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also known as nuclear-enriched transcript 2 (NEAT2), located on chromosome 11q13, is a long intergenic non-coding RNA (lincRNA) with .8,000 nts. 10 It was reported that MALAT1 is expressed abnormally and participated in the regulation of proliferation, migration, invasion, and apoptosis of many cancers, 11 such as non-small-cell lung cancer, 12 ESCC, 13 gastric cancer, 14 and hepatocellular carcinoma. 15 Single nucleotide polymorphisms (SNPs) were wellrecognized to directly regulate lncRNAs expression and alter the function of their corresponding lncRNAs. [16] [17] [18] Polymorphisms of MALAT1 had been reported to be associated with susceptibility to pulmonary arterial hypertension, 19 coronary atherosclerotic heart disease, 20 onset of congenital heart disease, 21 and colorectal cancer. 22 However, whether the polymorphisms of MALAT1 play any role in the risk of ESCC remains unknown. Considering that upregulation of lncRNA MALAT1 contributed to proliferation and metastasis in ESCC, 13 we performed a case-control study in the Chinese population to identify the association between MALAT1 polymorphisms and risk of ESCC.
Patients and methods study patients
A total of 245 ESCC patients diagnosed by pathology were consecutively recruited from Qilu Hospital of Shandong University from June to December 2017. Subjects diagnosed with more than one primary tumor were excluded from the study. Four hundred and ninety controls were selected from the physical examination center and matched to the ESCC patients by age (±5 years) and gender during the same time period. All participants were genetically unrelated. Data on basic characteristics (eg, age and gender) and environmental exposure (eg, smoking status and alcohol use) were obtained using face-to-face questionnaires and from patient records. Each participant donated 2 mL of venous blood willingly and provided informed consent to participate in the study.
The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Qilu Hospital.
snP selection and genotyping
SNPs in the MALAT1 genes were selected on the basis of the 1000 Genomes database (http://browser.1000genomes. org/Homo_sapiens/UserData/Haploview) and the software Haploview 4.2. Criteria of minor allele frequency (MAF) .0.05 was set to obtain the tag SNPs in the Chinese population. Ultimately, four candidate SNPs were chosen: rs3200401 C . T, rs1122709 C . G, rs664589 C . G, and rs619586 A . G. Genomic DNA was extracted from 2 mL of peripheral blood using a DNA Blood Mini Kit (#51104 QIAamp DNA Blood Mini Kit; Qiagen, NV, Venlo, the Netherlands) under the guidance of the manufacturer's protocol. Genotyping for the SNPs was done by using the TaqMan allelic discrimination assay on LightCycler 480 II system (Hoffman-La Roche Ltd., Basel, Switzerland). The primers used for amplification are shown in Table S1 , which were self-designed by Primer Express 3.0 (Thermo Fisher Scientific, Waltham, MA, USA). Genotyping was performed blindly and the results were analyzed by using Sequencher Software (version 5.4.5).
statistical analysis
The goodness-of-fit chi-squared test was used to test HardyWeinberg equilibrium (HWE) of SNPs among the control subjects. To determine the differences in the distribution of basic characteristics between the patients and controls, the selected exposure variables were evaluated using chi-squared tests. The association between MALAT1 polymorphisms and risk of ESCC was examined by computing the ORs and 95% CIs using logistic regression analysis and adjusting for smoking status and alcohol use. Besides presenting P-values, the false discovery rate (FDR) was also analyzed using the Benjamini and Hochberg method. 23 Since the main design of our study was to find the potential association between MALAT1 polymorphisms and risk of ESCC and considering the number of samples and SNPs that were included in our research, we set the FDR cutoff for noteworthy SNPs at 25% level. Statistical analysis was performed with SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
Results

Basic characteristics
Locus information regarding MALAT1 polymorphisms and MAF in controls is listed in Table S1 . Results showed that
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Qu et al the distribution of MALAT1 rs3200401 C . T, rs1122709 C . G, rs664589 C . G, and rs619586 A . G genotypes in controls agreed with HWE (P.0.05). Table S2 shows the basic characteristics of the 245 ESCC patients and 490 controls. Age and gender were not significantly different between the case and control groups (P=0.999, P=0.999), which indicated that these groups matched well with respect to these parameters. There was also no significant difference in the smoking status (P=0.439). However, the proportion of drinking was significantly higher in the case group compared with controls (P=0.012).
association of MalaT1 rs3200401 c . T, rs1122709 c . g, rs664589 c . g, and rs619586 a . g polymorphisms with escc risk
The genotype frequencies of MALAT1 rs3200401 C . T, rs1122709 C . G, rs664589 C . G, and rs619586 A . G polymorphisms are listed in Table 1 association of MalaT1 rs3200401 c . T, rs1122709 c . g, rs664589 c . g, and rs619586 a . g polymorphisms with escc risk in different stratification groups As is shown in Table 2 , stratification between rs3200401 and risk of ESCC according to smoking status and alcohol use was further conducted. In never drinking subgroup, after adjusting for smoking status, we found that rs3200401 CT/TT increased the risk of ESCC compared with CC genotype (TT vs CC: adjusted OR =2.34, 95% CI =1.02-5.34, P=0.044; CT/ TT vs CC: adjusted OR =1.52, 95% CI =1.02-2.26, P=0.041 [ Table 2 ]), which passed the correction of FDR (FDR =0.208, 0.208, respectively).
The genotype frequencies of MALAT1 rs619586 A . G polymorphism in the subgroup analysis are shown in Table 3 . In ever drinking subgroup, after adjusting for smoking status, rs619586 GG genotype was associated with a decreased risk of ESCC (GG vs AA: adjusted OR =0.38, 95% CI =0.15-0.99, P=0.049 [ Table 3 ]). However, the analysis did not pass the FDR correction (FDR =0.432).
In addition, after logistic regression analysis, rs1122709 G . C and rs664589 G . C polymorphisms were not associated with the risk of ESCC in any subgroup (Tables S3 and S4 ).
Discussion
The pathogenesis of ESCC is complex, and multiple factors may contribute to the etiology of ESCC. Our study indicated that MALAT1 polymorphisms were associated with a risk of ESCC in a Chinese population. We identified that rs3200401, a tag SNP of MALAT1, was a pivotal genetic risk factor against ESCC. Stratified analysis showed that in never drinking subgroup, rs3200401 TT and CT/TT genotype increased the risk of ESCC compared with CC genotype after adjusting for smoking status. All the results remained statistically significant after correction for FDR. In addition, in ever drinking subgroup, rs619586 GG genotype was associated with decreased risk of ESCC compared with AA, while the significance disappeared after adjusting for FDR. Further investigation was required to explore whether T allele of rs3200401 and G allele of rs619586 regulated MALAT1 expression in vivo. These results indicated that rs3200401 T allele and rs619586 G allele may be the key factors to influence the risk of ESCC.
MALAT1 was found to be overexpressed in numerous types of cancers including ESCC, 13 and MALAT1 showed significant effects on proliferation, migration, invasion, and apoptosis of cancer cells. 24 In clinical application, the upregulation of MALAT1 in several types of cancer tissues and its association with biological behavior of tumor cells made it a potential diagnostic or predictive biomarker. 6, 12, [25] [26] [27] MALAT1 co-localizes with SC35 splicing domains, indicating that it may function in RNA metabolism. 28 MALAT1 was found to participate in mRNA processing, splicing, and exporting. 29 Except for RNA spicing, MALAT1 functioned by regulating the expression of many pivotal genes, including melanoma inhibitory activity 2, roundabout 1, glypican 6, latrophilin 2, CUB domain containing protein 1 ATP-binding cassette, subfamily A, and member 1 in lung cancer, 30 and caspase-3, caspase-8, Bcl-2, and Bcl-2-associated X protein in cervical cancer cells, 31 thus promoting the development of cancer. In addition, MALAT1 interacted with many other genes and was involved in several signaling pathways (ATM-CHK2 pathway, 13 PI3K-AKT pathway, 31, 32 and ), thereby playing an important role in the progression of cancer cells. However, studies reporting on the underlying mechanisms are very few. Although our study found that rs3200401 C . T polymorphism was associated with increased risk of ESCC, it was also reported to be associated with better survival in advanced lung adenocarcinomas. 34 The opposite role of rs32000401 polymorphism 
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Qu et al in different cancers remains to be illuminated for detailed mechanism. It was reported that the interaction between lncRNAs and other molecules was probably associated with their structure, which might be altered by the polymorphisms of lncRNAs. 35 The rs3200401 C . T variant is located at the region M of MALAT1 (6,008-7,011 nts), one of the binding sites to SRSF2. 36 In addition, SRSF2 and phosphorylated SRSF2 were reported to be correlated with aggressive features of lung adenocarcinoma. 37 In a recent report, lncRNA SNP database was used to predict potential functions of rs3200401, suggesting that the C . T variation of rs3200401 causes 1.62 kcal/mol minimal free energy (ΔG) change and that it may alter the structural features of MALAT1, resulting in weakened interaction between MALAT1 and its binding protein SRSF2. 34 Besides, MALAT1 was reported to be associated with phosphorylation of SRSF2, interaction with SR proteins as a "molecular sponge," and regulation of the alternative splicing of pre-mRNAs. 28, 38 Taken together, it was biologically possible that SNP rs3200401 C . T may alter the expression levels of cancer-associated genes, thus participating in the carcinogenesis and cancer development. A previous report suggested that rs619586 A . G was associated with decreased cancer risk in a meta-analysis study, 39 which was in line with our findings. In pulmonary arterial hypertension, MALAT1 with rs619586 G allele was reported to function as a competing endogenous RNA which exhibits more affinity toward miR-214, consequently inhibiting the vascular endothelial cell proliferation and migration in vitro by shortening S-M phase transition. 19 Nevertheless, more studies are required to clarify the mechanism as to how SNPs of MALAT1 functioned in the development of cancers.
Several limitations existed in this study. First, because all the participants were selected from a local hospital, there was a potential possibility of selection and information 
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Qu et al bias. Therefore, we used stratified analysis as compensation. Second, the sample size of our study was relatively small, which might have impacted the statistical power. Furthermore, for the stratification analysis, a larger sample size including more areas is required to fully validate the results.
Conclusion
Our findings suggest that MALAT1 rs3200401 C . T polymorphism is associated with an increased risk of ESCC in a Chinese population, and that rs3200401 polymorphism could be a novel and effective predictive biomarker for ESCC. Also, there is a minor possibility that rs619586 A . G polymorphisms may be associated with decreased risk of ESCC.
Further studies in diverse ethnicities and functional analysis are required to confirm our findings.
Ethics approval and informed consent
All participants were informed about the purpose of the study and all signed the written informed consent. The study was approved by the Ethics Committee of Qilu Hospital of Shandong University and the study was conducted in accordance with the Declaration of Helsinki.
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